SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26.

Authors

Rolando Pajon¹, Nicole A Doria-Rose², Xiaoying Shen³, Stephen D Schmidt⁴, Sijy O'Dell⁴, Charlene McDanal³, Wenhong Feng³, Jin Tong³, Amanda Eaton³, Maha Maglinao¹, Haili Tang³, Kelly E Manning⁵, Venkata-Viswanadh Edara⁵, Lilin Lai⁵, Madison Ellis⁵, Kathryn M Moore⁵, Katharine Floyd⁵, Stephanie L Foster⁵, Christine M Posavad⁶, Robert L Atmar⁷, Kirsten E Lyke⁸, Tongqing Zhou⁴, Lingshu Wang⁴, Yi Zhang⁴, Martin R Gaudinski⁴, Walker P Black⁴, Ingelise Gordon⁴, Mercy Guech⁴, Julie E Ledgerwood⁴, John N Misasi⁴, Alicia Widge⁴, Nancy J Sullivan⁴, Paul C Roberts⁹, John H Beigel⁹, Bette Korber¹⁰, Lindsey R Baden¹¹, Hana El Sahly⁷, Spyros Chalkias¹, Honghong Zhou¹, Jing Feng¹, Bethany Girard¹, Rituparna Das¹, Anne Aunins¹, Darin K Edwards¹, Mehul S Suthar⁵, John R Mascola⁴, David C Montefiori³

Affiliations

¹ Moderna, Cambridge, MA.
² National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD.
³ Duke University Medical Center, Durham, NC.
⁴ NIAID, Bethesda, MD.
⁵ Emory University School of Medicine, Atlanta, GA.
⁶ Fred Hutchinson Cancer Research Center, Seattle, WA.
⁷ Baylor College of Medicine, Houston, TX.
⁸ University of Maryland School of Medicine, Baltimore, MD.
⁹ National Institutes of Health, Bethesda, MD.
¹⁰ Los Alamos National Laboratory, Los Alamos, NM.
¹¹ Brigham and Women's Hospital, Boston, MA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Grants and funding